| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Full Paper |
Département de Radiologie, Hôpital Saint-Luc du CHUM, 1058 St-Denis, Montreal, Quebec, H2X 3J4 Canada
Correspondence: Dr Y BoulangerPhD, Département de Radiologie, Hôpital Saint-Luc du CHUM, 1058 St-Denis, Montréal, Québec, H2X 3J4 Canada.
The assessment of the effectiveness of MRI-guided focused ultrasound surgery (MRIgFUS) of breast carcinomas can be performed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters which monitor the presence of residual tumour. The aim of this study was to evaluate the effect of the post-treatment delay on this assessment. DCE-MRI data were acquired immediately and 314 days after MRIgFUS treatment of 26 tumours (<7 days, n = 6;
ge;7 days, n = 20). The percentage of residual tumour was determined histologically on the resected mass and correlated with two DCE-MRI parameters: increase in signal intensity (ISI) and positive enhancement integral (PEI). No correlation could be found between DCE-MRI data acquired immediately after treatment and the percentage of residual tumour. Good correlation coefficients were found for data acquired several days after treatment (ISI, r = 0.749; PEI, r = 0.778). However, they were higher when the post-treatment time interval was 7 days or more (ISI, r = 0.962; PEI, r = 0.934). These results suggest that a post-treatment delay of 7 days is necessary for the accurate assessment of the presence of residual tumour by DCE-MRI parameters.
This article has been cited by other articles:
![]() |
D. Gianfelice, C. Gupta, W. Kucharczyk, P. Bret, D. Havill, and M. Clemons Palliative Treatment of Painful Bone Metastases with MR Imaging-guided Focused Ultrasound Radiology, October 1, 2008; 249(1): 355 - 363. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| BJR | DMFR | IMAGING | ALL BIR JOURNALS |